Acadia Pharmaceuticals | ACAD - Capital De Empréstimo





Capital De Empréstimo Alterar Data
Acadia Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 1.48B 1.2B 2026-03
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 247.21M 868.77M 2026-03
Eisai JPY 134.78B 12M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Incyte USD 29.41M 785K 2026-03
J&J USD 37.53B 1.91B 2026-03
Moderna USD 603M 7M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Pfizer USD 60.57B 1.08B 2026-03
Prothena USD 0 0 2024-12
PTC Therapeutics USD 286.94M 1.74B 2026-03
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12